Lead Product(s): Bamlanivimab
Therapeutic Area: Infections and Infectious Diseases Product Name: LY-CoV555
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 17, 2020
Lilly’s success in developing neutralizing antibodies against COVID-19, augmented with Samsung Biologics’ manufacturing scale, signals a major move forward in delivering important treatments to patients suffering from the deadly pandemic.